World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 4
Page: 830-845

A REVIEW ON NANOPARTICLES BASED DRUG DELIVERY SYSTEM OF CANCER THERAPY

[1]Rakesh Kumar Sahu, [2]Anshu Kumar, [3]Shubham Singh, [4]Saurav Kumar, [5]Nainsi Kumari, [6]Sindhu Raj Sinha, [7]Jaiprakash Kumar, [8]Ritesh Kumar Singh

[1]Assistant Professor, Mahadeva Lal Schroff College of Pharmacy Aurangabad, Bihar-824102.
[2]B. Pharm Final Year Students, Mahadeva Lal Schroff College of Pharmacy Aurangabad, Bihar-824102.

Article Received: 2 March 2026 | | Article Revised: 24 March 2026 | | Article Accepted: 13 April 2026

***Corresponding Author: Rakesh Kumar Sahu**
Assistant Professor, Mahadeva Lal Schroff College of Pharmacy Aurangabad Bihar-824102.
DOI: https://doi.org/10.5281/zenodo.19593738

How to cite this Article: Rakesh Kumar Sahu, Anshu Kumar, Shubham Singh, Saurav Kumar, Nainsi Kumari, Sindhu Raj Sinha, Jaiprakash Kumar, Ritesh Kumar Singh (2026) A REVIEW ON NANOPARTICLES BASED DRUG DELIVERY SYSTEM OF CANCER THERAPY. World Journal of Pharmaceutical Science and Research, 5(4), 830-845.

ABSTRACT

While targeted drug delivery represents a significant leap forward in oncology, its success is often hampered by the complex nature of tumor heterogeneity and the restrictive conditions of the local microenvironment. Nanotechnology provides a sophisticated solution to these hurdles, offering a platform for the high-precision targeting of malignant cells that spares healthy surrounding tissue. By engineering nanoparticles to bypass physiological barriers and navigate the tumor landscape, researchers can deliver therapeutic payloads directly where they are most needed. Strategic modifications to the nanoparticle surface—such as functionalization for better stability and extended circulation not only improve cellular uptake but also help overcome persistent clinical issues like multidrug resistance and poor penetration into dense, solid tumors. Because these systems can be programmed for controlled, sustained release, they ensure a more consistent therapeutic effect over time. Ultimately, the continued evolution of nanomedicine is paving the way for a paradigm shift toward personalized oncology, where treatments are specifically calibrated to the unique biological profile of each patient.

KEYWORDS: Nanoparticle, Targeted drug delivery systems, Lipid-based drug delivery, Cancer cells.

INTRODUCTION

The field of nanomedicine is rapidly evolving, with lipid-based nanoparticles emerging as a cornerstone for targeted drug delivery, particularly in the treatment of highly proliferative and treatment-resistant cancer cells. By encapsulating therapeutic agents within these lipid shells, researchers can direct medicine to specific tissues while minimizing off-target effects. Achieving this level of precision requires a meticulous optimization of the nanoparticle's physical

properties such as size, surface charge, and chemical composition to ensure both stability and safety.[1] This development process is inherently interdisciplinary, requiring a collaborative "feedback loop" between various scientific domains:

- Chemists engineer novel lipid formulations to improve the carrier's durability and biocompatibility.
- Biologists track how these particles move through the body, focusing on cellular uptake and intracellular trafficking.
- Clinicians evaluate the real-world performance of these systems in preclinical and clinical settings, identifying potential toxicity or efficacy gaps.

Despite this collaborative progress, significant biological hurdles remain. The human immune system and natural clearance mechanisms often recognize and remove nanoparticles before they reach their target, and there are ongoing concerns regarding the long-term accumulation of lipid carriers in vital organs. Beyond drug delivery, nanotechnology also offers multifunctional benefits, such as inducing localized hyperthermia to thermally destroy malignant cells and enhancing contrast for medical imaging to improve tumor monitoring. Overcoming the challenges of stability and organ-specific accumulation is the final, critical step in transitioning these revolutionary platforms from the laboratory to the bedside.[2]

2. The Importance of Drug Delivery in Nanomedicine

The integration of nanoparticles into drug delivery systems has revolutionized the ability to administer medications with high precision.[3] These systems shield therapeutic agents from premature biological degradation, ensuring that a higher concentration of the drug reaches the target site. This is particularly critical for treatments that must cross formidable physiological barriers, such as the blood-brain barrier (BBB), which has historically hindered the treatment of neurological disorders like Alzheimer’s disease.

By engineering nanoparticles for controlled release, clinicians can maintain therapeutic drug levels in the bloodstream for extended periods, reducing the frequency of dosing and improving patient compliance. Furthermore, the shift toward personalized medicine allows these delivery systems to be tailored to a patient's unique genetic profile, maximizing efficacy while minimizing adverse reactions.[4]

Table 1: Advantages of Nanoparticle-Based Drug Delivery vs. Conventional Therapy

Feature	Conventional Drug Delivery	Nanoparticle-Based Delivery
Targeting	Systemic (distributes throughout body)	Site-specific (targets tumor/tissue)
Side Effects	High (due to off-target toxicity)	Reduced (spares healthy tissues)
Drug Protection	Vulnerable to enzymatic degradation	Encapsulated and protected
Release Profile	Rapid peak and decline	Controlled and sustained release
Barrier Penetration	Limited (e.g., struggles with BBB)	Enhanced (engineered for penetration)

❖ Challenges and the Barrier of Resistance

Despite these advancements, the clinical application of nanomedicine faces a significant hurdle: acquired drug resistance. Over time, tumor cells may develop adaptive mechanisms to evade the cytotoxic effects of drugs delivered via nanoparticles.[5] This biological "pushback" necessitates the development of next-generation strategies to maintain treatment potency.

Table 2: Barriers to Efficacy and Proposed Solutions.

Challenge	Impact on Therapy	Research Strategy/Solution
Drug Resistance	Reduced sensitivity of tumor cells	Combination therapy using multiple nanoparticles
Immune Clearance	Rapid removal by the liver/spleen	Surface modification (e.g., PEGylation)
Tumor Heterogeneity	Uneven drug distribution in solid tumors	Ligand-mediated active targeting
Complex Fabrication	Difficulty in large-scale production	Optimization of methods like **melt sono crystallization**

3. Nanoparticle-Based Drug Delivery Systems

Nanoparticle-based drug delivery systems (NDDS) represent a paradigm shift in oncology, shifting from systemic exposure to site-specific intervention. The core theory of these systems relies on the Enhanced Permeability and Retention (EPR) effect, which exploits the "leaky" vasculature of tumors to allow nanoparticles to accumulate preferentially within malignant tissues while sparing healthy cells.[6]

❖ Theory of Overcoming Drug Resistance

One of the primary theoretical advantages of NDDS is the ability to bypass Multidrug Resistance (MDR). Conventional drugs often enter cells via passive diffusion and are recognized by efflux pumps (such as P-glycoprotein), which actively transport the drug back out of the cell. In contrast, nanoparticles enter the cell through endocytosis, effectively "smuggling" the therapeutic payload past these membrane-bound pumps.

Table 3: Mechanisms of Action for Enhanced Efficacy.

Mechanism	Theoretical Basis	Impact on Therapy
Active Targeting	Ligand-receptor binding (e.g., Folate)	Increases specificity for cancer cells.
Controlled Release	Diffusion or degradation-controlled	Maintains sustained drug levels within the therapeutic window.
Combination Delivery	Simultaneous encapsulation of multiple agents	Targets multiple oncogenic pathways to prevent resistance.
Gene Silencing	Delivery of siRNA or CRISPR components	Reverses genetic mutations that cause drug resistance.

❖ Theoretical Limitations and Heterogeneity

A critical counter-theory to the universal success of nanomedicine is tumor heterogeneity. Not all cancer cells within a single tumor react identically to nanoparticles. Some cells may undergo mutations that allow them to actively expel or neutralize the particles.[7] Additionally, dense stromal tissue in tumors (like pancreatic cancer) acts as a physical barrier, limiting the penetration depth of even the most sophisticated nanoparticles.

Table 4: Biological Barriers to Nanoparticle Efficacy

Barrier Type	Theoretical Challenge	Potential Consequence
Immune Clearance	Recognition by the Mononuclear Phagocyte System (MPS)	Rapid removal from circulation by the liver and spleen.
Interstitial Pressure	High fluid pressure within solid tumors	Hinders the inward diffusion of nanoparticles.
Cellular Variation	Genetic mutations/Heterogeneity	Variable uptake and efficacy across different cell populations.
Off-target Toxicity	Accumulation in healthy filtration organs	Potential long-term damage to the liver or kidneys.

3.1. Structure of the Nanoparticles

The therapeutic efficacy of a nanoparticle is not merely a result of its chemical payload but is deeply rooted in its structural architecture. Size, morphology, and surface chemistry are the primary determinants of how these systems interact with the immune system and navigate biological barriers.

❖ **Optimization of Biological Interaction**

By fine-tuning these structural properties, researchers can improve targeting efficiency for immunotherapies. For instance, nanoparticles within the 20–100 nm range are optimal for avoiding rapid renal filtration while still being small enough to penetrate the dense interstitial spaces of a tumor.[8]

Table 5: Impact of Structural Properties on Immunotherapy.

Structural Property	Biological Influence	Therapeutic Goal
Size	Affects rate of uptake by macrophages.	Minimize immune clearance; maximize tumor entry.
Shape	Influences "flow" through the microvasculature.	Improve circulation time and cellular internalization.
Surface Charge	Dictates protein corona formation.	Ensure colloidal stability and prevent aggregation.
Surface Ligands	Facilitates specific receptor binding.	Achieve high-precision active targeting.

3.2. Types of Nanoparticles Used in Drug Delivery

The selection of a nanoparticle type is largely dictated by the specific requirements of the cancer being treated. By utilizing different materials—ranging from organic lipids to inorganic metals—researchers can create specialized delivery systems tailored for either sustained release, high-resolution imaging, or both.

❖ **Polymeric and Lipid-Based Nanoparticles**

Polymeric nanoparticles, synthesized from biocompatible materials, are highly valued for their controlled release capabilities. These systems act as protective reservoirs for chemotherapy drugs, allowing for a steady therapeutic effect over an extended period.[9] Similarly, liposomes are frequently used due to their ability to encapsulate both hydrophobic and hydrophilic agents, making them highly versatile in clinical applications.

❖ **Metallic Nanoparticles: Innovation in Imaging and Therapy**

Metallic nanoparticles, particularly those composed of gold or silver, introduce unique physical and optical properties to cancer treatment. These particles can be functionalized with antibodies to specifically bind to cancer cell receptors, facilitating targeted delivery. Furthermore, their unique interactions with light allow them to be used in photoacoustic imaging, providing real-time monitoring of tumor progression.[10]

Table 6: Comparative Analysis of Nanoparticle Platforms.

Nanoparticle Type	Material Composition	Primary Therapeutic Advantage	Clinical Limitation
Polymeric	Synthetic/Natural Polymers	Predictable drug release; low toxicity.	Difficulties in large-scale synthesis.
Metallic	Gold, Silver, Iron Oxide	Superior imaging and thermal therapy.	High risk of organ accumulation.
Lipid-Based	Phospholipids/Cholesterol	High biocompatibility; easy to scale.	Potential for rapid immune clearance.



Figure 1: Comparative performance of Nanoparticle Categories.

3.3. Inorganic Nanoparticles

Inorganic nanoparticles represent a distinct class of nanomedicine, offering unique optical, magnetic, and electronic properties that are unattainable with organic counterparts. By engineering these particles, researchers can create "theranostic" platforms—systems that simultaneously provide high-resolution diagnostic imaging and targeted therapy.

❖ **Theoretical Synergy with Traditional Therapies**

Inorganic particles are particularly effective when used as sensitizers for chemotherapy and radiation. For instance, gold nanoparticles can be used to locally amplify radiation doses or generate localized heat (hyperthermia) when triggered by near-infrared light, physically destroying malignant cells from within.

Table 7: Properties and Clinical Challenges of Inorganic NPs.

Particle Type	Unique Property	Clinical Potential	Primary Barrier
Gold (Au)	Surface Plasmon Resonance	Photothermal therapy & Imaging	High cost of raw materials.
Silver (Ag)	Potent Antimicrobial/Cytotoxic	Synergistic chemotherapy enhancement	High oxidative stress induction.
Iron Oxide	Superparamagnetism	Targeted delivery via external magnets	Potential interference with MRIs.

❖ **Manufacturing and Scalability**

A significant hurdle in transitioning inorganic nanoparticles to the clinic is the scalability of production. Laboratory-scale synthesis often relies on batch processes that are difficult to standardize. To address this, researchers are moving toward continuous flow reactors, which allow for:

- Uniformity: Precise control over particle size and shape distribution.
- Cost-Effectiveness: Reduced waste and increased throughput.
- Reproducibility: Meeting the strict "Good Manufacturing Practice" (GMP) standards required for human trials.[11,12]

❖ **Overcoming Microenvironmental Barriers**

Despite their precision, inorganic nanoparticles face physical limitations in "difficult-to-treat" tumors, such as pancreatic cancer. The dense stromal tissue (the desmoplastic reaction) creates a high-pressure shield that prevents even the most advanced particles from penetrating deep into the tumor core.

3.4. Organic Nanoparticles

Organic nanoparticles (ONPs) are increasingly viewed as the preferred alternative to metallic systems due to their inherent biocompatibility and biodegradability. Composed of biological or carbon-based materials, ONPs can be engineered to mimic natural cellular components, allowing them to navigate the body's circulatory system with minimal immune provocation.[13]

❖ **Precision Targeting in Breast Cancer**

A hallmark of organic nanomedicine is the ability to functionalize the particle surface with specific proteins or ligands. For example, researchers have successfully developed ONPs coated with ligands that specifically recognize receptors on breast cancer cells. This "lock-and-key" mechanism ensures that high-potency anticancer drugs are delivered directly to the tumor, significantly inhibiting growth and preventing metastasis while sparing healthy tissue.[14]

Table 8: Advantages and Therapeutic Roles of Organic Nanoparticles.

Feature	Biological Benefit	Clinical Application
Biocompatibility	Low immunogenicity and systemic toxicity.	Safe for repeated long-term dosing.
Surface Engineering	Easy attachment of proteins and antibodies.	High-precision active targeting.
Controlled Release	Sustained diffusion through polymer matrix.	Maintains optimal drug levels in plasma.
Fluorescence	Diagnostic signaling capabilities.	Real-time imaging and tumor tracking.

❖ **The Dual Role: Theranostics and Imaging**

Beyond drug delivery, organic nanoparticles are potent tools for medical imaging. By incorporating fluorescent dyes or contrast agents, ONPs allow clinicians to visualize internal tissues and detect early-stage malignancies that might be missed by conventional scans.[15] This integration of therapy and diagnostics (theranostics) represents the cutting edge of personalized oncology.

❖ **Safety Concerns and Long-Term Effects**

Despite their organic nature, these systems are not entirely without risk. The potential for bioaccumulation in filtration organs and the unintended toxicity of certain fluorescent markers remain primary areas of concern.[16] Furthermore, the complexity of biological interactions means that even "safe" organic materials can occasionally trigger an adverse immune response if not carefully optimized.[17]

Table 9: Summary of Organic Nanoparticle Challenges.

Challenge	Impact	Research Priority
Stability	Potential for premature drug leakage.	Enhancing cross-linking and shell integrity.
Visualization	Background noise in fluorescent imaging.	Developing high-contrast, near-infrared dyes.
Metabolism	Variable degradation rates in patients.	Standardizing pharmacokinetic profiles.

3.5. Hybrid Nanoparticles

Hybrid nanoparticles represent a strategic fusion designed to overcome the individual shortcomings of organic and inorganic carriers. By integrating components like metals or metal oxides within an organic matrix (such as a lipid or polymer shell), researchers can create systems that offer superior imaging capabilities while maintaining high levels of biocompatibility.[18]

❖ **The Synergy of Materials**

The "hybrid" approach allows for multifunctional behavior. For instance, an inorganic core (like iron oxide) can provide magnetic resonance imaging (MRI) contrast, while the organic shell ensures the particle is not immediately recognized and cleared by the immune system.

Table 10: Synergistic Effects in Hybrid Systems.

Component	Primary Contribution	Benefit to Hybrid System
Inorganic Core	Structural rigidity & physical signaling	Enhanced imaging and thermal stability.
Organic Shell	Biocompatibility & functionalization	Reduced toxicity and improved drug loading.
Interface	Controlled interaction	Modulated drug release and protection of the core.

Immunogenicity and Physical Characteristics

- The immune response to hybrid systems is highly sensitive to the particle's physical geometry. While the organic coating is intended to "mask" the particle, the underlying size and shape still play a critical role in determining if the body triggers an inflammatory response.[19]
- Optimal Biocompatibility: Small, spherical nanoparticles with smooth surfaces are more likely to evade the mononuclear phagocyte system (MPS).[19]
- Inflammatory Triggers: Large, irregular, or "rough" surfaces often act as a mechanical stimulus for immune cells, potentially leading to chronic inflammation.

Table 11: Factors Influencing Hybrid Nanoparticle Immunogenicity.

Factor	Low Immune Response (Ideal)	High Immune Response (Risk)
Size	10–100 nm	>200 nm
Shape	Spherical / Uniform	Irregular / Sharp-edged
Surface	Smooth / PEGylated	Rough / Uncoated
Composition	Bio-inert Hybrid	Highly Reactive Metals

➢ **Contradictions in Biocompatibility**

Interestingly, recent studies have shown that traditional "rules" of biocompatibility are not absolute. For example, some gold nanoparticles can trigger inflammation regardless of their shape, while certain irregular inorganic particles show surprisingly low immunogenicity.[20] This highlights the necessity of a case-by-case toxicological assessment for every new hybrid formulation before moving to clinical trials.[21]

3.6. Advantages and Limitations of Nanoparticle Systems

Nanoparticle-based drug delivery systems (NDDS) represent a cornerstone of next-generation oncology. Their primary advantage lies in precision targeting, which allows for deeper penetration into tumor tissues and a significant increase in the therapeutic index of volatile anticancer agents.[22] By concentrating the drug at the site of the disease, NDDS drastically reduces the systemic exposure that leads to traditional chemotherapy's debilitating side effects.

Table 12: Core Advantages of Nanotechnology in Oncology.

Advantage	Mechanism	Clinical Outcome
Site-Specific Targeting	Ligand-receptor interactions.	Minimal damage to healthy tissues.
Controlled Release	Stimulus-responsive matrices (pH/Temp).	Sustained drug levels; fewer doses.
Multifunctionality	Simultaneous Imaging & Therapy.	Real-time monitoring of tumor response.
Overcoming MDR	Bypassing cellular efflux pumps.	Effective treatment of resistant cancers.

➢ **Critical Limitations and Barriers to Translation**

Despite these strengths, clinical translation is hindered by several "hard" biological limits. Immune recognition remains a primary hurdle; the mononuclear phagocyte system (MPS) often clears nanoparticles from the blood before they can reach the tumor.[23] Furthermore, the development of acquired drug resistance where cancer cells mutate or activate alternative signaling pathways can render even the most sophisticated nanocarriers ineffective over time.

Table 13: Key Limitations and Engineering Solutions.

Limitation	Technical Challenge	Research Strategy
Rapid Clearance	Recognition by liver/spleen.	PEGylation and "stealth" coatings.
Tumor Penetration	Dense stromal barriers.	Size-switchable or enzyme-responsive NPs.
Drug Resistance	Cellular adaptation/mutations.	Combination therapy & siRNA delivery.
Toxicity	Long-term bioaccumulation.	Use of biodegradable organic materials.

5. Polymer-Based Nanoparticles for Drug Delivery

Polymer-based nanoparticles (PNPs) are highly versatile platforms that address many of the pharmacokinetic limitations of traditional free drugs. By adjusting the monomer composition and molecular weight, these particles can be engineered for a specific controlled release mechanism, ensuring a constant therapeutic concentration over time.[24]

➢ **Advantages of PNPs**

The primary strength of PNPs lies in their surface functionalization. They can be easily conjugated with ligands or antibodies to target diseased cells specifically, which minimizes off-target toxicity and maximizes the "effective dose" that reaches the tumor.[25] Furthermore, their inherent biocompatibility and biodegradability allow for long-term use without the chronic accumulation risks associated with metallic particles.[26]

Table 14: Comparison of Clinical Polymer-Based Platforms.

Platform	Structural Characteristic	Primary Benefit	Clinical Application
Liposomes	Lipid bilayer vesicles	High biocompatibility; dual loading	General chemotherapy (Doxil)
Dendrimers	Highly branched / Tree-like	Precise control over surface groups	Gene therapy and diagnostics
Polymeric Micelles	Core-shell amphiphilic blocks	Solubilizes hydrophobic drugs	Solid tumor targeting

5.1. Clinical Variants: Dendrimers and Micelles

- Research into PNPs has branched into specialized structures designed for specific drug types:
- Dendrimers: These are monodisperse, symmetric macromolecules. Their branched structure provides a massive surface area for functional groups, allowing for a high degree of precision in drug release and targeting.[27]
- Polymeric Micelles: These self-assemble from amphiphilic copolymers into a core-shell shape. The hydrophobic core acts as a "safe haven" for insoluble drugs, protecting them from degradation, while the hydrophilic shell creates a "stealth" layer that prolongs circulation in the bloodstream.[28]

❖ **The Challenge of Off-Target Binding**

A significant theoretical hurdle is that healthy cells may express low levels of the same markers found on tumors. This can lead to off-target binding, where the delivery system unintentionally damages healthy tissue. To solve this, researchers are integrating advanced imaging with nanotechnology to create "multifunctional dendrimers" that require multiple signals (such as a specific marker and a specific pH) before releasing the drug.[29]

5.2. Advantages and Limitations: The Stimulus-Response Theory

PNPs offer unmatched customization, but their degradation is highly dependent on environmental factors like pH, temperature, and enzymes.

❖ **pH-Responsive Systems**

Because the tumor microenvironment is typically more acidic (pH approx 6.5) than healthy tissue (pH approx 7.4), researchers have developed pH-sensitive polymers. These particles remain stable in the blood but "trigger" or disassemble once they enter the acidic tumor space.

Table 15: Stimulus-Responsive Strategies

Stimulus	Trigger Mechanism	Research Strategy
pH Change	Acid-labile bond cleavage	pH-sensitive polymer shells.
Enzymatic	Matrix degradation by Proteases	Enzyme-responsive peptide linkers.
Magnetic	External magnetic field	Combining PNPs with iron oxide cores.
Thermal	Localized hyperthermia	Temperature-sensitive polymer blocks.

❖ **Overcoming Heterogeneity in pH**

The primary limitation of this theory is that pH levels are not uniform across different tumors or even within the same tumor mass.[30] To achieve more reliable results, scientists are adding "stimulus-responsive moieties" to the polymer backbone. This ensures the particle only responds to very narrow, specific pH shifts, preventing the premature release of the drug in non-target areas.[31]

6. Drug Loading and Encapsulation Strategies

The methodology used to load a drug into a nanoparticle (NP) is a primary determinant of the system's stability and release profile. Researchers select a loading technique based on the drug's solubility, molecular weight, and the desired therapeutic timeline.

6.1. Loading Methodologies

There are three primary theoretical approaches to loading:

- Encapsulation: The drug is physically trapped within the NP matrix or core during synthesis (e.g., via coacervation or self-assembly). This provides the highest level of protection against biological degradation.[32]
- Adsorption: The drug is chemically or physically attached to the surface of a pre-formed NP. While easier to manufacture, it often leads to a "burst release" where the drug detaches too quickly.[33]
- Conjugation: The drug is covalently bonded to the nanoparticle surface or polymer backbone. This allows for the most precise control over release, as the bond only breaks under specific conditions (like a change in pH).[34]

Table 16: Comparison of Drug Loading Techniques.

Method	Mechanism	Primary Advantage	Major Limitation
Co-precipitation	Simultaneous drug/polymer precipitation.	High loading efficiency for hydrophobic drugs.	Difficult to control particle size.
Self-Assembly	Spontaneous formation based on polymer traits.	Simple process; maintains drug integrity.	Limited to specific amphiphilic polymers.
Drug Conjugation	Chemical covalent bonding.	Zero premature leakage; targeted release.	Complex chemistry; may alter drug activity.

6.2. Tumor Targeting and Stimuli-Responsive Release

Once loaded, the nanoparticle must differentiate between healthy tissue and a tumor. This is achieved through two complementary theories: Active Targeting and Stimuli-Response.

Active Targeting via Surface Functionalization

- By attaching ligands (like folic acid) or antibodies to the NP surface, the particle acts as a "homing missile" that only binds to receptors over-expressed on cancer cell membranes. This reduces non-specific distribution and lowers the risk of systemic side effects.

❖ **Stimuli-Responsive "Triggered" Release**

To ensure the drug is only released at the target site, nanoparticles are engineered to respond to the unique Tumor Microenvironment (TME).

- pH-Triggered Release: Tumors are typically acidic (pH approx 6.5). NPs designed with acid-labile bonds remain "locked" in the neutral blood (pH approx 7.4) but "unlock" and release their payload once they encounter the acidic conditions of the tumor.
- Thermal Triggering: Some NPs release drugs in response to localized heat, which can be applied externally to the tumor site.

Table 17: Mechanisms of Site-Specific Activation.

Trigger	Biological/Physical Rationale	Therapeutic Goal
Acidic pH	Lower pH in tumor interstitial fluid.	Prevent drug release in healthy blood/tissue.
Redox Potential	High Glutathione levels inside cancer cells.	Intracellular release of DNA-damaging agents.
Enzymatic	Overexpression of Matrix Metalloproteinases.	Degradation of NP shell only at the tumor site.

6.3. Diagnostic Integration and Nanosensors

The versatility of loaded nanoparticles extends beyond therapy into diagnostics. "Lab-on-a-chip" devices and biosensors utilize nanotechnology to detect minute traces of cancer biomarkers in blood or saliva.[35] This allows for earlier detection and a more personalized treatment strategy. However, a significant clinical challenge remains: biomarker non-specificity. Some markers may be present in non-cancerous conditions, leading to potential misdiagnosis.[36,37]

7. Targeted Nanoparticle Drug Delivery

The evolution of targeted delivery seeks to solve the "magic bullet" problem in oncology: maximizing lethal impact on tumors while rendering the treatment invisible to healthy tissues. Modern approaches utilize Nanogels hydrophilic, crosslinked polymer networks that act as "smart" reservoirs. These nanogels are engineered to remain collapsed and stable in the bloodstream but swell and discharge their cargo upon encountering the specific pH of a tumor.[38]

7.1. Methodologies of Delivery: ADCs and Liposomes

Beyond synthetic nanoparticles, two other major platforms dominate the targeting landscape:

- Antibody-Drug Conjugates (ADCs): These combine the high specificity of monoclonal antibodies with the potency of cytotoxic drugs. They circulate until they find a matching cancer cell marker.[39]
- Liposomes: These lipid vesicles can be "cloaked" in polymers to avoid immune detection, delivering drugs directly into the cell membrane.



Figure 2: Schematic Representation of Neutralization, Aggregation, and Precipitation.

Table 18: Comparison of Targeted Delivery Platforms.

Platform	Targeting Mechanism	Primary Advantage	Major Challenge
Nanogels	Swelling/Deswelling (pH)	High drug loading; soft tissue compatibility.	Potential for premature leakage.
ADCs	Ligand-Receptor binding	Exceptional cellular specificity.	Complex and expensive synthesis.
Liposomes	Membrane fusion	Excellent biocompatibility.	Low stability in long-term circulation.

7.2. Passive Targeting and the EPR Effect

Passive targeting does not rely on "homing" molecules. Instead, it exploits the unique anatomy of tumor tissue. Malignant tumors grow rapidly, creating leaky blood vessels with large gaps (fenestrations) and poor lymphatic drainage.[40]

This phenomenon, known as the Enhanced Permeability and Retention (EPR) effect, allows nanoparticles to seep out of the blood and become trapped within the tumor mass.[41,42]

- Advantage: Simple design; no need for complex surface chemistry.
- Limitation: High interstitial fluid pressure in some tumors can push nanoparticles back out, and "leakiness" varies significantly between different cancer types.

7.3. Active Targeting: Precision Engineering

Active targeting involves "decorating" the surface of the nanoparticle with ligands, such as antibodies, peptides, or small molecules like folic acid. These ligands function as keys that only fit the "locks" (receptors) overexpressed on the surface of cancer cells.[43]

Table 19: Active Targeting vs. Passive Targeting.

Feature	Passive Targeting	Active Targeting
Driver	Physical/Anatomical (EPR Effect)	Biochemical (Ligand-Receptor)
Specificity	Tissue-level (Tumor mass)	Cellular-level (Specific cancer cells)
Complexity	Low	High (Surface functionalization)
Efficiency	Dependent on tumor vascularization	Dependent on receptor expression levels

❖ **Overcoming Resistance with Combination Strategies**

A critical limitation of active targeting is receptor heterogeneity not all cancer cells in a tumor express the same markers. To counter this, researchers are developing Multi-Targeting Nanoparticles that carry two or more different ligands, ensuring that even mutated or "marker-negative" cells are neutralized. This is often paired with Gene Therapy, which can be used to "re-sensitize" resistant cells by modifying their genetic makeup to make them more vulnerable to the nanoparticle's payload.[43,44]

8. Recent Developments in Nanoparticle-Based Drug Delivery

The recent landscape of oncology has been redefined by the synergy between nanotechnology and Immunotherapies. While nanoparticles excel at delivering toxic payloads to specific molecular markers, researchers are now using them to modulate the immune system itself. This dual approach not only targets existing tumors but also aims to prime the body to prevent tumor recurrence.[45]

➢ **The Rise of Immune Checkpoint Inhibitors**

A major breakthrough in this field is the use of Immune Checkpoint Inhibitors (ICIs). These agents block specific proteins (like PD-1 or CTLA-4) that cancer cells use to "hide" from the immune system. By removing these "brakes," the immune system can recognize and destroy malignant cells more effectively.[46]

Table 20: Breakthroughs in Nano-Immunotherapy.

Development	Mechanism	Clinical Impact
Nano-ICIs	Targeted delivery of checkpoint blockers.	High response in advanced melanoma and lung cancer.
Cancer Vaccines	Nanoparticles delivering tumor antigens.	Potential for long-term "immune memory" against recurrence.
STING Agonists	Activating innate immune pathways via NPs.	Turning "cold" tumors "hot" (immune-active).

9. Cancer Nanodrug Delivery Challenges

While nanotechnology has revolutionized treatment, it faces a gauntlet of biological "filters" and barriers that can reduce therapeutic efficacy or cause unintended harm.[47]

9.1. The Immunotherapy-Risk Paradox

One emerging area of concern is the long-term impact of systemic immune activation. Specifically, researchers are investigating whether certain immunotherapies could paradoxically influence breast cancer risk factors in women.[48]

- The Concern: Could prolonged immune stimulation inadvertently affect healthy breast tissue?
- The Research: Ongoing longitudinal studies track patients for several years, comparing risk factor changes in those receiving immunotherapy versus control groups.
- The Counter-finding: Interestingly, some subsets of patients show a decrease in risk factors, likely due to a complex interplay of genetics, lifestyle, and individual drug response.

9.2. Physical and Biological Barriers to Delivery

The Tumor Microenvironment (TME) remains the most formidable obstacle for nanodrugs. Even with perfect targeting ligands (antibodies, peptides, or aptamers), the following factors hinder progress:

- The Extracellular Matrix (ECM): A dense "web" of collagen and proteins that physically blocks nanoparticles from

spreading through the tumor.

- Abnormal Vasculature: Unlike healthy vessels, tumor blood vessels are chaotic and pressurized, often pushing nanodrugs away from the tumor core.[49]
- Tumor Heterogeneity: A "one-size-fits-all" antibody-targeted nanoparticle (targeting a specific antigen) will fail if only 50% of the tumor cells express that antigen.

Table 21: Summary of Technical Hurdles and Solutions.

Challenge	Impact on Therapy	Engineering Solution
Heterogeneity	Undetected/untreated cell clusters.	Multi-target (bispecific) nanoparticles.
ECM Density	Limited penetration to the tumor core.	Protease-conjugated NPs to "digest" the matrix.
Immune Clearance	NP build-up in liver/spleen.	Biomimetic (cell-membrane coated) "stealth" NPs.
Off-target Toxicity	Damage to healthy tissues.	Highly specific "AND-gate" logic targeting.

CONCLUSION

The integration of nanotechnology with modern oncology represents a transformative shift in the treatment of various diseases, specifically through the development of lipid-based and polymeric nanoparticles designed for high-precision drug delivery. These systems are engineered to encapsulate therapeutic agents, protecting them from premature biological degradation and facilitating their transport directly to tumor sites while sparing healthy tissues. To ensure both the efficacy and safety of these platforms, researchers meticulously optimize physical attributes such as particle size, surface charge, and chemical composition, which dictate how a nanoparticle interacts with the immune system and navigates complex physiological barriers like the blood-brain barrier. This development process is inherently interdisciplinary, relying on a collaborative feedback loop where chemists synthesize stable lipid or polymer matrices, biologists track cellular uptake and intracellular trafficking, and clinicians evaluate therapeutic outcomes and potential toxicities in real-world settings.

Despite significant preclinical and clinical promise, several biological and technical hurdles remain. A primary challenge is the tumor microenvironment itself, where a dense extracellular matrix and chaotic, pressurized vasculature act as a physical shield that prevents nanodrugs from penetrating the tumor core. Furthermore, tumor heterogeneity—where different cells within the same mass express varying levels of targeted antigens—can render single-ligand delivery systems ineffective. Beyond simple drug transport, the field is evolving toward multifunctional "theranostic" platforms that combine therapy with diagnostic imaging or localized hyperthermia to physically destroy malignant cells. To overcome persistent issues like drug resistance and rapid immune clearance, current research is pivoting toward stimulus-responsive "smart" nanoparticles and combination therapies that target multiple oncogenic pathways simultaneously. Ultimately, the successful translation of these cutting-edge technologies from the laboratory to the bedside depends on standardizing manufacturing processes and developing personalized medicine strategies calibrated to the unique genetic profile of each individual patient.

REFERENCES

1. S. Zhnag, R. Langer Enteric elastomer enables safe gastric retention and extended oral drug delivery for improved medication adherence Nanomed. Nanotechnol. Biol. Med., 2018; 14: p. 1841.
2. J.R. McCarthy, F.A. Jaffer The role of nanomedicine in the imaging and therapy of thrombosis Nanomedicine (N. Y., NY, U. S.), 2011; 6: 1291-1293.
3. W. Zou, A. McAdorey, H. Yan, W. Chen Nanomedicine to overcome antimicrobial resistance: challenges and

prospects. Nanomedicine (N. Y., NY, U. S.), 2023; 18: 471-484.

4. S. Venkatraman, T. Wong How can nanoparticles be used to overcome the challenges of glaucoma treatment Nanomedicine (N. Y., NY, U. S.), 2014; 9: 1281-1283.
5. Badea New strategies in melanoma therapy: can nanoparticles overcome chemoresistance Nanomedicine (N. Y., NY, U. S.), 2017; 12: 1623-1626.
6. Wang, C. Chen Light-activated mesoporous nanocarriers to overcome drug resistance of cancer cells Nanomed. Nanotechnol. Biol. Med., 2016; 12: p. 519.
7. G. Piret, C.N. Prinz Could the use of nanowire structures overcome some of the current limitations of brain electrode implants Nanomedicine (N. Y., NY, U. S.), 2016; 11: 745-747.
8. B.B. Rajeeva, R. Menz, Y. Zheng Towards rational design of multifunctional theranostic nanoparticles: what barriers do we need to overcome Nanomedicine (N. Y., NY, U. S.), 2014; 9: 1767-1770.
9. G. PourGashtasbi Nanotoxicology and challenges of translation Nanomedicine (N. Y., NY, U. S.), 2015; 10: 3121-3129.
10. S.T. Yurkin, Z. Wang Cell membrane-derived nanoparticles: emerging clinical opportunities for targeted drug delivery Nanomedicine (N. Y., NY, U. S.), 2017; 12: 2007-2019.
11. R. Huang Peptide-mediated drug delivery systems for targeted glioma therapy Nanomed. Nanotechnol. Biol. Med., 2016; 12: p. 535.
12. Y. Doleyres Benefits of branched polymeric nanoparticles for enhanced targeted drug delivery Nanomed. & Nanotech. Open Access, 2020; 5.
13. M. Talelli, W.E. Hennink Thermosensitive polymeric micelles for targeted drug delivery Nanomedicine (N. Y., NY, U. S.), 2011; 6: 1245-1255.
14. M.K. Viswanadh, M.S. Muthu Targeted bioadhesive nanomedicine: an effective approach for synergistic drug delivery to cancers Nanomedicine (N. Y., NY, U. S.), 2018; 13: 1401-1403.
15. K. Vyas, M. Rathod, M.M. Patel Insight on nano drug delivery systems with targeted therapy in treatment of oral cancer Nanomed. Nanotechnol. Biol. Med., 2023; 49.
16. D.S. Benoit, H. Koo Targeted, triggered drug delivery to tumor and biofilm microenvironments Nanomedicine (N. Y., NY, U. S.), 2016; 11: 873-879.
17. P. Li, D. Wang, J. Hu, X. Yang The role of imaging in targeted delivery of nanomedicine for cancer therapy Adv. Drug Deliv. Rev., 2022; 189.
18. M. Lin, L. Teng, Y. Wang, J. Zhang, X. Sun Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy Drug Deliv., 2015; 23: 1420-1425.
19. D. Koppers-Lalic, M.M. Hogenboom, J.M. Middeldorp, D.M. Pegtel Virus-modified exosomes for targeted RNA delivery; A new approach in nanomedicine Adv. Drug Deliv. Rev., 2013; 65: 348-356.
20. S. Trigueros Nanoscale metal particles as nanocarriers in targeted drug delivery system J. Nano Res., 2016; 4.
21. P. Jaiswal, B. Gidwani, A. Vyas Nanostructured lipid carriers and their current application in targeted drug delivery, Artificial Cells, Nanomed Biotech, 2014; 44: 27-40.
22. Y. Li, G. Deng, X. Hu, C. Li, X. Wang, Q. Zhu, K. Zheng, W. Xiong, H. Wu Recent advances in mesoporous silica nanoparticle-based targeted drug-delivery systems for cancer therapy Nanomedicine (N. Y., NY, U. S.), 2022; 17: 1253-1279.
23. R. Juneja, I. Roy Iron oxide-doped niosomes as drug carriers for magnetically targeted drug delivery Int. J.

Nanomed., 2018; 13: 7-9.

24. M. Lin, L. Teng, Y. Wang, J. Zhang, X. Sun Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy Drug Deliv., 2015; 23: 1420-1425.
25. L. Ao, L. Huang, W. Su Composite magnetic nanocarriers for MRI and targeted drug delivery Nanomed. Nanotechnol. Biol. Med., 2016; 12: 490-491.
26. T.W. Wong Use of microwave to improve nanomedicine application on skin Expet Opin. Drug Deliv., 2016; 14: 283–283.
27. G. Sahay, NanoDDS Engineering the next wave of nanomedicine and drug delivery systems Adv. Drug Deliv. Rev., 2018; 144(2019): 1-2.
28. S. Puri, M. Mazza, G. Roy, R.M. England, L. Zhou, S. Nourian, J. Anand Subramony Evolution of nanomedicine formulations for targeted delivery and controlled release Adv. Drug Deliv. Rev. 2023.
29. R. Müller Junghanns, Nanocrystal Technology, Drug Delivery and Clinical Applications Inter J of Nanomed, 2008; p. 295.
30. L.M. Bonanno, E. Segal Nanostructured porous silicon–polymer-based hybrids: from biosensing to drug delivery Nanomedicine (N. Y., NY, U. S.), 2011; 6: 1755-1770.
31. Y.-K. Oh, J. Huang Editorial: graphene-based materials in nanomedicine Adv. Drug Deliv. Rev., 2016; 105: 107-108.
32. E. Fattal, F. Fay Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases Adv. Drug Deliv. Rev., 2021; 175.
33. J. Ding, X. Chen Functional polymer nanocarriers for rational antitumor drug delivery Nanomed. Nanotechnol. Biol. Med., 2018; 14: 1875-1876.
34. E. Nance Careers in nanomedicine and drug delivery Adv. Drug Deliv. Rev., 2019; 144: 180-189.
35. Y. Sun, C. Kang, F. Liu, Y. Zhou, L. Luo, H. Qiao RGD peptide-based target drug delivery of doxorubicin nanomedicine Drug Dev. Res., 2017; 78: 283-291.
36. J. Dobson Magnetic micro- and nano-particle-based targeting for drug and gene delivery Nanomedicine (N. Y., NY, U. S.), 2006; 1: 31-37.
37. Q. Liu, J. Du Asymmetrical polymer vesicles for significantly improving MRI sensitivity and cancer-targeted drug delivery Nanomed. Nanotechnol. Biol. Med., 2016; 12: p. 483.
38. M. Swierczewska, H.S. Han, K. Kim, J.H. Park, S. Lee Polysaccharide-based nanoparticles for theranostic nanomedicine Adv. Drug Deliv. Rev., 2016; 99: 70-84.
39. T.M. Nguyen, S. Lee, S.B. Lee Conductive polymer nanotube patch for fast and controlled ex vivo transdermal drug delivery Nanomedicine (N. Y., NY, U. S.), 2014; 9: 2263-2272.
40. F. Shakeel Editorial: nanomedicine-based drug delivery systems: recent developments and future prospects Molecules, 2023; 28: p. 4138.
41. J. Ouyang, S. Rao, R. Liu, L. Wang, W. Chen, W. Tao, N. Kong 2D materials-based nanomedicine: from discovery to applications Adv. Drug Deliv. Rev., 2022; 185.
42. M. Michalak, P. Kurcok, M. Hakkarainen Polyhydroxyalkanoate-based drug delivery systems Pol. Internet, 2016; 66: 617-622.
43. D.A. Hafez, K.A. Elkhodairy, M. Teleb, A.O. Elzoghby Nanomedicine-based approaches for improved delivery of phyto-therapeutics for cancer therapy Expet Opin. Drug Deliv., 2020; 17: 279-285.

44. Z. Chen, X. Lai, S. Song, X. Zhu, J. Zhu Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy Drug Deliv., 2015; 23: 1369-1373.
45. M.K. Viswanadh, M.S. Muthu Targeted bioadhesive nanomedicine: an effective approach for synergistic drug delivery to cancers Nanomedicine (N. Y., NY, U. S.), 2018; 13: 1401-1403.
46. M.K. Viswanadh, M.S. Muthu Targeted bioadhesive nanomedicine: an effective approach for synergistic drug delivery to cancers Nanomedicine (N. Y., NY, U. S.), 2018; 13: 1401-1403.
47. Z. Chen, X. Lai, S. Song, X. Zhu, J. Zhu Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy Drug Deliv., 2015; 23: 1369-1373.
48. P.J. Harrison, H. Wieslander, A. Sabirsh, J. Karlsson, V. Malmsjö, A. Hellander, C. Wählby, O. Spjuth Deep-learning models for lipid nanoparticle-based drug delivery Nanomedicine (N. Y., NY, U. S.), 2021; 16: 1097-1110.
49. J. Li, L. Sun, Y. Liu, H. Yao, S. Jiang, YunzhuPu, Y. Li, Y. Zhang To reduce premature drug release while ensuring burst intracellular drug release of solid lipid nanoparticle-based drug delivery system with clathrin modification Nanomed. Nanotechnol. Biol. Med., 2019; 15: 108-118.